Matrix metalloproteinase

Crescent Innovations Offers Breakthrough Osteoarthritis Treatment Technology for Sale, and its impact on Orthopedics

Retrieved on: 
星期二, 四月 30, 2024
OA, Sale, Knee, Hyaluronic acid, Osteoarthritis, Matrix metalloproteinase, ISO, Polyelectrolyte, Confidentiality

WESTFORD, Mass., April 30, 2024 /PRNewswire-PRWeb/ -- Crescent Innovations Inc. announced today the sale of its Poly-gamma-glutamic Acid (PgGA) technology related to osteoarthritis (OA), plus various intellectual property and know-how assets.

Key Points: 
  • WESTFORD, Mass., April 30, 2024 /PRNewswire-PRWeb/ -- Crescent Innovations Inc. announced today the sale of its Poly-gamma-glutamic Acid (PgGA) technology related to osteoarthritis (OA), plus various intellectual property and know-how assets.
  • "Crescent Innovations has shown, both in vitro and in vivo, that...PgGA...reduce[s] MMPs and other inflammatory marker[s] far greater than HA."
  • Al Prescott, President Crescent Innovations Inc.
    PgGA was developed as the next generation of viscosupplements for treat degenerative joint disease.
  • Crescent Innovations has shown, both in vitro and in vivo, that this allows PgGA to reduce MMPs and other inflammatory marker far greater than HA.

tvScientific Launches Retail Performance TV

Retrieved on: 
星期三, 十一月 15, 2023
Singular, Television, Head, Data science, Learning, History, Matrix metalloproteinase, Social media, CTV, Partnership, Geography, Growth, Online shopping, Video game

PASADENA, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- tvScientific , the preeminent performance advertising platform for connected TV (CTV), today announced the launch of Retail Performance TV, a retail media solution that enables advertisers to leverage granular retail data including foot traffic, purchase history and location-specific interests to target CTV ad campaigns on a cost-per-outcome basis.

Key Points: 
  • PASADENA, Calif., Nov. 15, 2023 (GLOBE NEWSWIRE) -- tvScientific , the preeminent performance advertising platform for connected TV (CTV), today announced the launch of Retail Performance TV, a retail media solution that enables advertisers to leverage granular retail data including foot traffic, purchase history and location-specific interests to target CTV ad campaigns on a cost-per-outcome basis.
  • By blending synthetic retail data from a variety of sources in tvScientific’s CTV targeting and measurement platform, retailers can target television advertisements to specific households according to their search and purchase history while factoring in retail store visits, unlocking unheard-of levels of performance.
  • “Retail Performance TV leverages the most powerful retail-level data - purchase history and geography - to serve ads on the most powerful channel available: television,” said Jason Fairchild, CEO of tvScientific.
  • “The ability to activate this kind of rich data on a one-to-one basis on the biggest, brightest screen in the household represents an entirely new capability for advertisers.”
    The launch of Retail Performance TV follows the ongoing transition of the $72 billion TV advertising market to programmatic execution, as technologies emerge that enable the buying and measurement of TV advertising in a manner similar to the $200 billion search and social media market.

Mark Farrah Associates Assessed the 2024 Competitive Medicare Advantage Market

Retrieved on: 
星期一, 十月 30, 2023
Professional Services, Health, Insurance, Health Insurance, Finance, General Health, Banking, MA, Special needs plan, Special needs, Data, MFA, Single-nucleotide polymorphism, Centers for Medicare & Medicaid Services, PDP, Matrix metalloproteinase, Medicare (United States), Medicare, AEP, Health insurance

Mark Farrah Associates (MFA), www.markfarrah.com , released an analysis presenting a brief assessment of the 2024 Medicare market landscape.

Key Points: 
  • Mark Farrah Associates (MFA), www.markfarrah.com , released an analysis presenting a brief assessment of the 2024 Medicare market landscape.
  • With the 2024 Annual Election Period (AEP) well underway, health plans invested in Medicare Advantage (MA) business have been eagerly marketing their products to attract more seniors.
  • MFA reported 5,805 distinct MA plan offerings are in the market lineup for the current 2024 AEP.
  • This includes MA plans, Medicare Advantage with prescription drug plans (MAPDs), Medicare/Medicaid plans (MMPs), and Special Needs Plans (SNPs).

Alcoa Corporation Reports Third Quarter 2023 Results

Retrieved on: 
星期三, 十月 18, 2023
Engineering, Mining, Minerals, Manufacturing, Natural Resources, Other Manufacturing, Steel, Adjustment, Security (finance), Biodiversity, Inventory, MMP, Kwinana, WA, EDT, AGL Energy, Environmental protection, Public expenditure, AGL, EBITDA, Carbon, GAAP, Maintenance, International Council, ICMM, Rehabilitation, Portland aluminium smelter, Drinking water, Matrix metalloproteinase, DWC, Account, Willowdale, International Council on Mining and Metals, State government, Pharmaceutical industry, Aluminium, Fine chemical, Cryptocurrency, Rare-earth element, Aluminium oxide, Metal

Net loss attributable to Alcoa Corporation was $168 million, or $0.94 per share.

Key Points: 
  • Net loss attributable to Alcoa Corporation was $168 million, or $0.94 per share.
  • Additionally, the third quarter results include the benefit of a $58 million valuation allowance reversal on the deferred tax assets of the Company’s subsidiaries in Iceland.
  • Alcoa disclosed before an August 2023 deadline its progress for applicable facilities, in accordance with the ICMM Conformance Protocol.
  • Alcoa will hold its quarterly conference call at 5:00 p.m. Eastern Daylight Time (EDT) on Wednesday, October 18, 2023, to present third quarter 2023 financial results and discuss the business, developments, and market conditions.

Regenerex Pharma, Inc. Corporate and Management Structure Update

Retrieved on: 
星期四, 九月 28, 2023
Nursing, Medical Supplies, Biotechnology, Health, Women, Pharmaceutical, Men, Research, Hospitals, Consumer, Science, CE, Pharma, Matrix metalloproteinase, Multimedia, Potassium chloride, OTC, Abrasion, Pressure, Ulcer, Burns, FDA, Environment, Wound healing, Silk, Pharmaceutical industry

Regenerex Pharma, Inc. (OTC: RGPX), announces the establishment of its comprehensive management team and the commencement of the Company manufacturing plans in Q4 2023.

Key Points: 
  • Regenerex Pharma, Inc. (OTC: RGPX), announces the establishment of its comprehensive management team and the commencement of the Company manufacturing plans in Q4 2023.
  • Regenerex Pharma’s products heal wounds effectively with its proprietary innovative formulas in the shortest period of time to minimize the chances of future complications.
  • The products have shown to be very effective in healing chronic wounds in multiple clinical evaluations with 95% of wounds demonstrating 100% closure within 90 days.
  • All of our products feature our proprietary QBx™ ingredients which contribute to setting up a suitable environment to allow wounds to close.

DolCas Biotech Obtains its First Non-GMO Project Verified Label for MMP-50®

Retrieved on: 
星期三, 九月 13, 2023
ASC, DNA, Communication, Medicine, Human, Mineral, Matrix metalloproteinase, Aquaculture Stewardship Council, Bureau of Oceans and International Environmental and Scientific Affairs, Marketing, Horse, NSF, The Non-GMO Project, Matrix metalloproteinase inhibitor, GMO, Lipid, USP, Certification, Economic methodology, Vitamin, Beauty, Tilapia, USDA, Mukai Cold Process Fruit Barrelling Plant, Dog, Micronutrient, Health, Environment, News, NMI, Aquaculture, Dietary supplement

LANDING, N.J., Sept. 13, 2023 /PRNewswire/ -- DolCas Biotech, LLC obtains its first Non-GMO Project-verified label for MMP-50®, a cold-processed, DNA-verified, and clinically researched New England green lipped mussel extract for human and pet health. MMP-50 is one of seven clinically researched ingredients in the innovative company's portfolio, and while MMP-50 is the first to receive the backing of the prestigious certification, CEO and founder, K. G. Rao affirms the company's plans to pursue the certification across its portfolio.

Key Points: 
  • LANDING, N.J., Sept. 13, 2023 /PRNewswire/ -- DolCas Biotech, LLC obtains its first Non-GMO Project-verified label for MMP-50®, a cold-processed, DNA-verified, and clinically researched New England green lipped mussel extract for human and pet health.
  • The transparency efforts the Non-GMO Project spearheaded on the food front has translated to the supplement market.
  • DolCas voluntarily submitted MMP-50 for compliance evaluation with the Non-GMO Project standard.
  • Like the Non-GMO Verified Project, the ASC certificate is the most highly merited of third-party credentialing in its category.

tvScientific Launches Cost-Per-Outcome CTV Ad Buying Through Partners

Retrieved on: 
星期四, 八月 17, 2023
Singular, Advertising, Matrix metalloproteinase, Partnership, Rakuten, Data science, Head, CTV, CJ Affiliate, TV, Fairchild, MoneyGram, MMM, CPA, Fender, ROI, Social media, CPO, Saatchi Art, Experian, Crocs, Groupon

PASADENA, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- tvScientific , the performance advertising platform for connected TV (CTV), announced today that brands and advertisers can now purchase CTV ad campaigns on a Cost-Per-Outcome (CPO) basis through leading partners Awin/Shareasale, Commission Junction, Impact, Partnerize, Partnerstack and Rakuten.

Key Points: 
  • PASADENA, Calif., Aug. 17, 2023 (GLOBE NEWSWIRE) -- tvScientific , the performance advertising platform for connected TV (CTV), announced today that brands and advertisers can now purchase CTV ad campaigns on a Cost-Per-Outcome (CPO) basis through leading partners Awin/Shareasale, Commission Junction, Impact, Partnerize, Partnerstack and Rakuten.
  • With CPO buying through tvScientific’s partners, advertisers are able to align their actual ad spend to marketing goals and only pay for outcomes that align with their desired results.
  • The new capability solidifies tvScientific as the leading global technology company for driving measurable ROI through CTV campaigns.
  • “We are very pleased with our growing roster of customers, partners and technical capabilities, and look forward to showing more brands across industries what’s possible with CTV.”

Alcoa Corporation Reports Second Quarter 2023 Results

Retrieved on: 
星期三, 七月 19, 2023
Engineering, Mining, Minerals, Manufacturing, Natural Resources, Other Manufacturing, Steel, Inventory, Maintenance, Matrix metalloproteinase, Account, SAN, WA, Portland aluminium smelter, State government, GAAP, EDT, ASI, Certification, Public expenditure, EPA, Environmental protection, EBITDA, United Steelworkers, Risk, DWC, Sun Indalex Finance, LLC v United Steelworkers, Security (finance), EGA, Adjustment, Willowdale, Cryptocurrency, Aluminium, Pharmaceutical industry, Fine chemical, Insurance, Clothing, Property management, Aluminium oxide, Kwinana

Third-party shipments in the second quarter of 2023 include alumina purchased to offset lower production.

Key Points: 
  • Third-party shipments in the second quarter of 2023 include alumina purchased to offset lower production.
  • Western Australia Mine Plan Approvals: During the second quarter of 2023, the Company continued to work with relevant state government agencies to support the annual mine approvals process.
  • The second quarter 2023 included favorable foreign currency gains of $40 million that may not recur.
  • Alcoa will hold its quarterly conference call at 5:00 p.m. Eastern Daylight Time (EDT) on Wednesday, July 19, 2023, to present second quarter 2023 financial results and discuss the business, developments, and market conditions.

Kochava Publisher’s Suite Selected by Major Industry Publishers

Retrieved on: 
星期二, 六月 20, 2023
Software, Professional Services, Internet, Data Management, Apps, Applications, Technology, Digital Marketing, Publishing, Data Analytics, Marketing, Advertising, Content Marketing, Communications, Matrix metalloproteinase, Omnichannel, CTV, OTT, Samsung, MNTN, IOS, Traction, SKAN, NBCUniversal, Growth, Roku, Sales, Spotify

Kochava , the leading real-time data solutions company for omni-channel attribution and measurement, today announced the Kochava Publisher’s Suite has been selected by and successfully integrated with major platforms and publishers.

Key Points: 
  • Kochava , the leading real-time data solutions company for omni-channel attribution and measurement, today announced the Kochava Publisher’s Suite has been selected by and successfully integrated with major platforms and publishers.
  • “This marks a significant milestone for our Publisher’s Suite since we launched last year,” said Charles Manning, Founder and CEO, Kochava.
  • The Kochava Publisher’s Suite also seamlessly integrates with all other mobile measurement partners (MMPs) to offer a flexible solution for publishers.
  • The Kochava Publisher’s Suite provides clear-labeled ad measurement tech for owned and operated inventory across leading platform-direct and publisher-direct offerings.

Late-Breaking Turn Biotechnologies Presentation at ISID to Show Cell Reprogramming with ERA™ Technology Renews Skin

Retrieved on: 
星期三, 五月 10, 2023
Matrix metalloproteinase, Paul Khavari, ISID, Matrix metalloproteinase inhibitor, Regeneration, Research, Cell, Messenger, ERA, Cellular senescence, Oxidative stress, International Society for Infectious Diseases, Extracellular matrix, ECM, Wound healing, Shinjuku, Epigenetics, Shinjuku NS Building, Skin, JST, Medical device, Dermatology, Ageing

MOUNTAIN VIEW, Calif., May 10, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell reprogramming company developing novel mRNA medicines for untreatable, age-related conditions, has been invited to present data showing that its epigenetic reprogramming technology rejuvenates human skin.

Key Points: 
  • MOUNTAIN VIEW, Calif., May 10, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell reprogramming company developing novel mRNA medicines for untreatable, age-related conditions, has been invited to present data showing that its epigenetic reprogramming technology rejuvenates human skin.
  • Turn Bio's late-breaking abstract was accepted for presentation during the prestigious International Societies for Investigative Dermatology (ISID) Meeting, in Tokyo, Japan.
  • Data will show that transient reprogramming with Turn Bio's Epigenetic Reprogramming of Aging (ERA™) technology rejuvenates cells within the extracellular matrix (ECM), resulting in comprehensive changes related to improved skin quality and structure.
  • Turn Bio data will be presented by Dr. Edward Hsia, vice president of Dermatology at Turn Bio.